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ABSTRACT: Multiple sclerosis (MS) is an autoimmune,
demyelinating disease of the central nervous system that can
cause loss of motor function and is thought to result, in part,
from chronic inflammation due to an antigen-specific T cell
immune response. Current treatments suppress the immune
system without antigen specificity, increasing the risks of
cancer, chronic infection, and other long-term side effects. In
this study, we show treatment of experimental autoimmune
encephalomyelitis (EAE), a model of MS, by coencapsulating
the immunodominant peptide of myelin oligodendrocyte glycoprotein (MOG) with dexamethasone (DXM) into acetalated
dextran (Ac-DEX) microparticles (DXM/MOG/MPs) and administering the microparticles subcutaneously. The clinical score of
the mice was reduced from 3.4 to 1.6 after 3 injections 3 days apart with the coencapsulated microparticulate formulation (MOG
17.6 μg and DXM 8 μg). This change in clinical score was significantly greater than observed with phosphate-buffered saline
(PBS), empty MPs, free DXM and MOG, DXM/MPs, and MOG/MPs. Additionally, treatment with DXM/MOG/MPs
significantly inhibited disease-associated cytokine (e.g., IL-17, GM-CSF) expression in splenocytes isolated in treated mice. Here
we show a promising approach for the therapeutic treatment of MS using a polymer-based microparticle delivery platform.
KEYWORDS: multiple sclerosis, microparticle, immunotherapy, acetalated dextran
■ INTRODUCTION
Multiple sclerosis (MS) is a chronic inflammatory disease in the
central nervous system (CNS) affecting approximately 2.5
million people worldwide.1 MS is thought to be induced by
macrophage (Mφ), and the T cell infiltrates to localized areas,
causing demyelination of axonal regions,2 possibly in a myelin-
specific manner.3 T cells secreting interferon γ (IFN-γ),
interleukin 17 (IL-17), or TH17 cells have been determined
to exacerbate the disease.4,5 New and emerging treatments for
MS have successfully targeted this subset of cells responsible for
inflammation in the CNS; however most treatments have
serious side effects.
Current common treatments for MS are generally effective at
decreasing relapses; however there are serious concerns due to
their nonspecific suppression of the immune system.
Natalizumab (Tysabri) is a monoclonal antibody treatment
that blocks leukocyte migration into the CNS6 but can lead to
immunosuppressive related diseases such as progressive
multifocal leukoencephalopathy (PML).7 Another treatment,
beta IFN (Betaseron; Extavia, Avonex, and Rebif), creates
neutralizing antibodies toward endogenous IFN8 and has been
shown to decrease relapse rates, but it does not stop overall
disease progression.9 Fingolimod (GILENYA) is an oral
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treatment that inhibits migration of naıv̈e T cells out of the
peripheral lymph nodes,10 but side effects related to
immunosuppression have been seen clinically.11 Long-term
treatment with immunosuppressive drugs can lead to an
increased risk of cancer12 and infection,13 illustrating the need
to develop new therapies that limit not only relapse rates and
disease progression, but also provide antigen specific
immunosuppression.
Therapies have been developed to treat in an antigen specific
manner, thereby limiting suppression of the entire immune
system. Antigen specific tolerance has been accomplished
through interaction with mucosal surfaces by oral,14,15 nasal,16
and sublingual17 delivery to treat animal models. Additionally,
tolerance has been achieved through ex vivo antigen pulsing of
dendritic cells.18 The mechanism of how antigen specific
tolerance forms varies but usually involves the generation of
either regulatory CD4 T cells that can inhibit cellular
inflammatory responses19 or inflammatory cell anergy.20 Even
though these methods have been successful preclinically, they
have failed once they have reached the clinics, likely due to an
inaccurate choice of antigen or issues with dosing quantities or
timing.21 Based on this lack of success, new methods for
treatment that can be applied to deliver a broad array of
antigens or allow for sustained release of antigens are desired.
Recently, Kang et al. have shown that, injecting both an
immunodominant peptide of insulin with dexamethasone
(DXM), they were able to prevent the onset of Type 1
Diabetes in a regulatory T cell manner.22 By immunizing with
an antigen and an “immune tolerizing” adjuvant, Kang et al.
were able to generate immune tolerance toward a self-antigen.
Others have built on this success, by using biomaterial-based
antigen-specific immunomodulatory formulations that protect
mice from experimental autoimmune encephalomyelitis
(EAE),23−27 a model of MS, and inflammatory arthritis via
antigen specific t-regulatory cell activation.28 Studies using
potential treatments for EAE have rarely examined the outcome
after administration at a clinically relevant time point. A recent
review by Vesterinen et al. showed approximately 4% of EAE
papers, out of the 126 studied, examine treatment efficacy
beyond 2 weeks post induction of EAE.29 Unfortunately, this
implies the vast majority of studies begin treatment prior to
symptom onset. Two recent studies use particle-based
postinduction treatments to ameliorate a relapsing and
remitting form of EAE. Yeste et al. utilized nonbiodegradable
gold nanoparticles injected intraperitoneally to treat EAE, and
Getts et al. induced tolerance through intravenous injection of
microparticles with surface conjugation of an encephalogenic
peptide.24,26 Although both studies are promising, alternate
methods optimizing particle formulation and function should
be explored. The goal of this work was to build on this existing
research to formulate a clinically relevant antigen specific
therapy utilizing a biodegradable polymer, FDA-approved
immunosuppressive drug, and a disease-associated antigen.
Traditionally, only phagocytic cells such as antigen presenting
cells (APCs) can internalize microparticles.30 By encapsulating
an immunosuppressive drug and an antigen in a microparticle,
only APCs can internalize the particles, which then could
induce an adaptive immune response that results in tolerance
against the autoimmune antigen.
Expanding on the previous work we formulated micro-
particles with the novel acid sensitive polymer, acetalated
dextran (Ac-DEX).31−33 Ac-DEX is derived from dextran by
modifying the hydroxyl groups with pendant acetals. Since
acetals are sensitive to acidic conditions, in low pH conditions
present in the lysosome of APCs, Ac-DEX microparticles
degrade releasing their cargo inside the lysosome. Previous
nanoparticulate formulations24,26 used surface bound proteins
which may be exposed to degradation in vivo, such as low pH or
enzymatic degradation. Our proposed acetalated dextran (Ac-
DEX) formulation can be an improvement upon this because
not only is the protein or peptide encapsulated, but we have
also shown enhanced protein stability across a broad range of
temperatures when a protein is encapsulated in Ac-DEX.34 We
use Ac-DEX to formulate a first of its kind polymer-based
particulate delivery vehicle coencapsulating a major MS target
antigen, myelin oligodendrocyte glycoprotein (MOG), and an
immunosuppressive drug, DXM, in an effort to treat MS. The
efficiency of encapsulated DXM delivery to APCs was
determined in vitro using nitric oxide (NO) and cytokine
measurements. To determine the protective properties of our
particles in vivo, they were administered as a treatment to
C57Bl/6 mice with EAE, and their effect on IL-17 and GM-
CSF production by these mice was examined through an
antigen recall assay.
■ MATERIALS AND METHODS
Materials. All reagents were purchased from Sigma-Aldrich
(St. Louis, MO) unless otherwise noted. Water (dd-H2O) for
buffers was purified using a Millipore (Billerica, MS) Milli-Q
Integral water purification system, which was made basic by
addition of triethylamine (TEA) (0.01% v/v). DXM (98%) was
purchased from Alfa Aesar (Ward Hill, MS), and MOG35−55
peptide was purchased from CS Bio Co. (Menlo Park, CA).
Antibodies used for ELISA and FLOW cytometry were
acquired from BD Biosciences (San Jose, CA), unless otherwise
specified. Fluorescence measurements were detected using a
Molecular Devices (Sunnyvale, CA) FlexStation 3, courtesy of
the Department of Chemistry and Biochemistry at the Ohio
State University and Molecular Devices SoftMax Pro Software
(Sunnyvale, CA).
Animals. Mice used for experiments were 10 week old
C57Bl/6 females purchased from Taconic Farms (Hudson,
NY). All animals were kept in a sterile facility according to The
Ohio State University Institutional Guidelines. All animal
procedures were in accordance with and approved by the
Institutional Animal Care and Use Committee (IACUC) of
The Ohio State University.
Cell Lines. RAW 264.7 macrophages were purchased from
ATCC (Manassas, VA) and cultured according to the
manufacturer specifications. Bone marrow derived dendritic
cells (BMDCs) were prepared as previously described.14
Synthesis and Analysis of Acetal Coverage of Ac-DEX.
Ac-DEX was synthesized using 71 kDa dextran as previously
described.33 Cyclic acetal coverage was determined to be 51.9%
by nuclear magnetic resonance as previously described.31
Preparation of Empty or DXM-Loaded Ac-DEX Micro-
particles. To formulate microparticles (MPs) containing
DXM, Ac-DEX (100 mg) and DXM were dissolved in
chloroform and ethanol (95:5 v/v, respectively) and mixed
with 3% polyvinyl alcohol (PVA) (MW ∼ 13−23 kg/mol, 87−
89% hydrolyzed) in phosphate-buffered saline (PBS). This
solution was probe sonicated (Branson Sonifier 450, Branson,
Los Angeles, CA) in an ice bath with a flat tip for 30 s with max
energy 30W. MPs were stirred for 2 h in 0.3% PVA in PBS and
were washed and collected by centrifugation at 18 000 rpm for
16 min on a Beckman Coulter Avanti J-E centrifuge (Brea,
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CA). Empty MPs (/MPs) were formulated in the same
manner, excluding the addition of DXM.
Preparation of MOG or MOG/DXM Co-Encapsulated
Ac-DEX MPs. DXM (1 mg) and Ac-DEX (100 mg) were
dissolved in chloroform and ethanol (95:5 v/v, respectively),
and MOG peptide (1 mg) in PBS was added. The mixture was
probe sonicated in an ice bath with a flat tip at with max energy
at 30 W for 30 s; 3% PVA in PBS (2 mL) was added, and the
mixture was probe sonicated for a second time. MPs were
stirred for 2 h in 0.3% PVA in PBS and were washed and
collected by tangential flow filtration using a mPES MidiKros
Filter Module (500 kD pore size, 235 cm2 surface area)
(Spectrum Laboratories, Rancho Dominguez, CA). MOG MPs
(MOG/MPs) were formulated by the same mechanism without
the addition of DXM.
Scanning Electron Microscopy (SEM). The microparticle
size and morphology were characterized by SEM using an FEI
NOVA nanoSEM (Hillsboro, OR). SEM sample preparation
and analysis was done as previously described.30
Quantification of DXM. Quantification of DXM for in vitro
assays was performed by liquid chromatography−mass
spectrometry (LCMS) with a Thermo Scientific Accela Pump
and Finnigan TSQ Quantum Discovery Max and analyzed
using LCquan software. MPs were dissolved in acetonitrile (1
mg/mL), purified by centrifugation for 5 min at 15 000g, and
passed through a 0.2 μm filter. Samples were run in a mobile
phase of acetonitrile−ddH2O−formic acid (50:49.9:0.1 v/v)
through a Thermo Scientific 2.5 μm × 100 × 100 C18 column
with a C8 guard column in isocratic mode with a flow rate of
0.2 mL/min. Desoxymethasone, the internal standard, and
dexamethasone were quantified using ion reaction monitoring
at 25% collision energy with ion transitions m/z 377 → 339
and m/z 393 → 237, respectively.
Quantification of DXM in DXM/MPs and DXM/MOG/
MPs was determined by high-performance liquid chromatog-
raphy (HPLC) with a method adapted from Zhang et al.35 MPs
were dissolved in a methanol−ddH2O solution (80:20 v/v) (1
mg/mL), and DXM concentration was determined using an
Agilent 1100 series HPLC (Santa Clara, California) with a
Thermo Scientific 150 mm × 4.6 mm, pore size 5 μm, Aquasil
C18 column (Waltham, MS). Samples were passed through the
column at a flow rate of 1 mL min−1 in a mobile phase of
methanol−ddH2O (80:20 v/v). DXM was detected at a
wavelength of 240 nm. Sample peaks were compared to a
standard curve and analyzed using Aglient Chemstation
software. DXM/MP encapsulation was 3.5%, and DXM/
MOG/MP was 1.5%.
Quantification of Encapsulated MOG. Samples of either
MOG MPs (MOG/MP), MOG, or /MPs (1 mg) were
suspended in 990 μL of PBS, and the pH was lowered with 5
μL of 50% formic acid (v/v). Samples were incubated on a 37
°C shaker plate overnight, and the solution was returned to
neutral pH using 13.25 M sodium hydroxide. The encapsula-
tion efficiency was determined using a fluorescamine assay per
the manufacturer’s instructions.
In Vitro Release of Dexamethasone. DXM/MPs were
suspended in either sodium acetate buffer (pH 5.0) or PBS (pH
7.4) at a concentration of 1 mg/mL. Samples were incubated
on a 37 °C shaker plate, and aliquots were withdrawn at each
time point, centrifuged (15 000g for 5 min), and supernatant
collected and freeze-dried. DXM quantification was performed
using LCMS (above).
Nitrite Analysis. Nitrite concentrations in supernatants
from RAW 264.7 macrophages cultured with LPS and DXM
were determined using Griess reagent from Promega (Madison,
WI). Macrophages were seeded in a 96-well plate at 5 × 104
cells/well with Thermo Scientific HyClone DMEM/high
glucose (Logan, UT) with 5% fetal bovine serum and 1%
penicillin/streptomycin (complete media) and left overnight to
adhere. Cells were cultured with LPS (10 μ/mL) for 24 h, then
treated with empty MPs or varying concentrations of DXM
(0−0.1 μM), in the form of DXM/MPs or free DXM, for 24 h.
Supernatants were collected after 24 h and centrifuged at 15
000 rpm for 10 min to remove residual particles and cells, then
analyzed with Griess reagent in accordance with the
manufacturer’s protocol.
Measurement of Il-6 Secreted by Bone Marrow
Derived Dendritic Cells (BMDCs). BMDCs were seeded at
a concentration of 5 × 104 cells/well in a 96-well plate,
stimulated with LPS (1 μg/mL) for 24 h, and then treated with
various concentrations of DXM or DXM/MPs (0−0.5 μM).
Supernatants were collected after 24 h and centrifuged at 15
000 rpm for 10 min to pellet residual cells and particles. The
level of IL-6 was measured by ELISA per the manufacturer’s
specifications.
Immunization and Treatment of EAE. Mice were
immunized with a complete Freund’s adjuvant (CFA) and
MOG peptide emulsion along with pertussis toxin, purchased
from Hooke Laboratories (Lawrence, MS), per the manufac-
turer’s suggestions. After immunization, mice were given
clinical scores as previously described36 and treated 18, 21,
and 24 days post immunization with 100 μL injections of either
PBS, /MPs, DXM/MPs (8 μg DXM), MOG/MPs (17.6 μg
MOG), DXM/MOG/MPs (8 μg DXM and 17.6 μg MOG), or
free DXM (8 μg) with free MOG (17.6 μg). On day 32 post
immunization mice were euthanized and their spinal cord,
spleens, and inguinal lymph nodes removed.
Measurement of Secreted IL-17 and Granulocyte-
Macrophage Colony-Stimulating Factor. Splenocytes from
treated mice were plated at 5 × 106 cells/well in a 12-well plate
and stimulated for 24 h with 2 μg/mL MOG. Supernatants
were isolated, and ELISA was performed on Immulon 2 plates
(Fisher Scientific) to determine the levels of IL-17 and
Granulocyte-macrophage colony-stimulating factor (GM-CSF)
as previously described.37
Fluorescence Activated Cell Sorting Analysis. Cells
from the spinal cord, spleen, and inguinal lymph node of the in
vivo mouse study were seeded at approximately 5 × 106 cells/
well in a 12-well plate and stimulated with 2 μg/mL MOG for
24 h. Approximately 1 × 106 cells were removed and placed in a
96-well plate for staining of intracellular IL-17, IFN-γ, and
FoxP3. Cells were treated with FACS buffer (1X PBS, 1%
ethylenediaminetetraacetic acid (EDTA), and 0.2% heat
shocked sterile FBS) and FC-receptor blocker (BD Bio-
sciences), followed by addition of surface antibodies. Cells were
fixed and permeabilized with Cytofix/Cytoperm (BD Bio-
sciences) for 30 min at 4 °C, then stained for IL-17, IFN-γ, and
FoxP3. Flow cytometry was performed with a FACSCanto II
flow cytometer (BD Biosciences) and analyzed using FlowJo.
■ RESULTS
Particle Formulation and Analysis. Figure 1 shows
electron micrographs of DXM/MOG/MPs (Figure 1A),
DXM/MPs (Figure 1B), and MOG/MPs (Figure 1C). Table
1 reports encapsulation efficiencies of DXM, MOG, or both in
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Ac-DEX MPs as well as quantity of drug per milligram of
particles. DXM was loaded with higher efficiency into DXM/
MPs compared with DXM/MOG/MPs (3.5% versus 1.5%),
and MOG/MPs showed increased encapsulation of MOG
compared with DXM/MOG/MPs (42% versus 21.8%). The
release of DXM from DXM/MPs incubated in either pH 5.0 or
pH 7.4 buffers is shown in Figure S1.
In Vitro Immunosuppressive Function of Dexametha-
sone. Figure 2 shows the effect of DXM on nitric oxide (NO)
release from Mϕ stimulated with LPS. Mϕ were cultured with
ranging doses of DXM (0−0.1 μM) in the form of free DXM or
DXM/MPs. There was no significant difference between any of
the groups at the 0 μM or /MPs groups. DXM/MPs
significantly decreased the amount of NO compared with free
DXM (p < 0.01 except p < 0.001 for 0.05 and 0.1 μM).
Inhibition of IL-6 production (Figure 3) in LPS stimulated
C57Bl/6 BMDCs was significantly decreased at 0.01 and 0.1
μM with DXM/MPs when compared with free DXM (p < 0.05
and p < 0.005, respectively).
In Vivo Treatment of EAE. Figure 4 shows average clinical
score data for mice treated with either PBS, /MPs, DXM/MPs,
MOG/MPs, or DXM/MOG/MPs 18 days post immunization.
Mice receiving injections of DXM/MOG/MPs had significantly
lower clinical scores compared to mice receiving any other
treatment type. All other treatment groups showed no
significant difference in clinical score from each other. As
analyzed with an ELISA, splenocytes stimulated with 2 μg/mL
MOG peptide after removal from DXM/MOG/MPs treated
mice showed significantly lower levels of IL-17 (Figure 5) when
compared with mice treated with /MPs (p < 0.05), DXM/
MOG (p < 0.05), DXM/MPs (p < 0.005), or MOG/MPs (p <
0.05). Also, with the exception of DXM/MOG, splenocytes
from mice treated with DXM/MOG/MPs also had significantly
lower levels of GM-CSF (Figure 5), when compared with mice
treated with PBS (p < 0.05), /MPs (p < 0.05), DXM/MPs (p <
0.005), or MOG/MPs (p < 0.05). There was no significant
difference in in FoxP3, IL-17 or IFN-γ levels measured by flow
cytometry in the spinal cord (Figure S2), inguinal lymph node
(Figure S3), or spleen (Figure S4 and S5) cells.
■ DISCUSSION
Scanning electron micrographs show the particles encapsulating
MOG, DXM, or DXM and MOG display relatively spherical
morphology and heterogeneity (Figure 1). Encapsulation
efficiencies (EE) for DXM/MPs and MOG/MPs were greater
than when the therapeutics were coencapsulated (DXM/
MOG/MPs; Table 1). Variability with amount of therapeutics
encapsulated in polymeric particles has been shown to affect
EE. Uchida and Goto showed that the EE of OVA in PLGA
microparticles increased proportionally with theoretical drug
loading; however after a certain point, large loading attempts
resulted in decreased efficiencies.38 Additionally, Fan et al. were
able to encapsulate DXM in poly(D,L-lactic acid) (PLA)
microparticles with efficiencies near 70%, but as attempts at
increased drug loading were made, the efficiencies also
decreased.39 This data suggests there may potentially be a
maximum loading, which could explain our diminished loading
of DXM and MOG in DXM/MOG/MPs compared with
DXM/MPs and MOG/MPs.
MP size seems to have little effect on DXM EE. Hickey et al.
were able to encapsulate DXM (8 μg/mg PLGA) in PLGA
microspheres ranging from 1 to 50 μm; however they still only
achieved 3−4% EE.40 Krishnan et al. used nanoprecipitation to
formulate copolymer particles using poly(ethylene glycol)
(PEG) and poly(ε-caprolactone) (PCL). Although DXM
encapsulation did slightly increase the particle size upon
Figure 1. Scanning electron micrographs of acetalated dextran (Ac-
DEX) microparticles encapsulating (A) dexamethasone (DXM) +
myelin oligodendrocyte glycoprotein35−55 (MOG), (B) DXM, or (C)
MOG.
Table 1. Encapsulation Efficiencies for Ac-DEX Particles
Containing DXM, MOG, or Both
Ac-DEX
encapsulation efficiency μg drug per mg MPs
formulation DXM MOG DXM MOG
DXM/MOG/MP 1.5% 21.8% 1.4 4.8
DXM/MP 3.5% n/a 3.6 n/a
MOG/MP n/a 42.0% n/a 7.5
Figure 2. Nitric oxide (NO) release by macrophages when cultured
with lipopolysaccharide plus free or encapsulated dexamethasone
(DXM) in Ac-DEX. The significance with respect to free DXM is
presented as * p < 0.01 and ** p < 0.001. Data are presented as the
average ± standard deviation.
Figure 3. Interleukin (IL)-6 production in culture from C57Bl/6
bone-marrow derived dendritic cells cultured in the presence of
lipopolysaccharide and with free dexamethasone (DXM) or DXM
encapsulated in Ac-DEX microparticles. The significance with respect
to free DXM is presented as * p < 0.05 and ** p < 0.005. Data are
presented as the average ± standard deviation.
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loading (from 111 to 127 nm), the particles displayed a high EE
of DXM (52.6%), while still maintaining small size and
dispersion.41 It is clear that DXM loading efficiencies and
particle sizing vary greatly based on polymer usage, formulation
technique, and drug loading quantity; therefore further work
should be performed to optimize formulation methods used in
this paper.
To evaluate the bioactivity of DXM/MPs we monitored the
release of pro-inflammatory nitric oxide (NO) in Mϕ
stimulated with LPS, in vitro. Macrophages cultured with
DXM/MPs had significantly lower NO production compared
to those cultured with free DXM (Figure 2). DXM/MP
treatment also diminished the response of LPS-stimulated
BMDC’s in vitro, which was illustrated by decreasing levels IL-6
(Figure 3). Inhibition of IL-6 has been shown to have a
protective effect in mice immunized with EAE, possibly through
the inhibition of TH17-mediated CNS infiltration of autor-
eactive cells.42 Increased DXM levels were able to decrease the
amount of IL-6 produced by BMDCs; however, only at 0.01
and 0.1 μM were DXM/MPs able to significantly inhibit IL-6
production compared to free DXM. This trend suggests MPs
Figure 4. Clinical scores of 9 week old C57Bl/6 female mice immunized with experimental autoimmune encephalomyelitis (EAE) on day 0. Mice
were treated after symptoms began by subcutaneous injections of PBS, empty microparticles (/MP), dexamethasone (DXM) MPs (DXM/MP),
DXM with myelin oligodendrocyte glycoprotein peptide (MOG), MOG MPs (MOG/MP), or DXM/MOG/MP on days 18, 21, and 24
postimmunization (as indicated with arrows). Treatments with DXM contained 8 μg of DXM and treatments with MOG contained 17.6 μg of
MOG. The statistical significance with respect to DXM/MOG/MP is presented as * p < 0.05. Data are presented as the average ± standard
deviation.
Figure 5. Antigen recall measurements of interleukin (IL)-17 and granulocyte macrophage colony-stimulating factor (GM-CSF) production from
splenocytes isolated from C57Bl/6 mice immunized for experimental autoimmune encephalomyelitis (EAE) and treated with PBS, empty
microparticles (/MP), dexamethasone MPs (DXM/MP), free DXM, and myelin oligodendrocyte glycoprotein (MOG) MPs (MOG/MP) or DXM/
MOG/MPs on days 18, 21, and 24 postimmunization. The significance with respect to DXM/MOG/MP is presented as * p < 0.05 and ** p <
0.005. Data are presented as average ± standard deviation.
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containing DXM may inhibit IL-6 more efficiently at high
levels.
Our study found mice therapeutically treated with DXM/
MOG/MPs at 18, 21, and 24 days post immunization displayed
significantly decreased mean clinical scores compared to mice
receiving PBS, /MPs, DXM/MPs, MOG/MPs, or free DXM
with free MOG (Figure 4). Since diagnostics recognizing MS
prior to symptom onset have yet to be developed, the MP
treatment was administered after the mean clinical score for
each group was approximately 3.5. A clinical score of 4
represents mice that no longer have hind limb function, while
clinical scores of 3 indicate severely deficient motor function of
the hind limbs. Mice receiving DXM/MOG/MPs improved to
a mean clinical score of 1.8, 16 days after the final injection, and
maintained this clinical score throughout the remainder of the
trial (Figure 4). A clinical score between 1 and 2 indicates the
mice have limpness in their tails, but their hind limb function
ranges from normal to slightly inhibited. This improvement in
clinical score was significantly lower than all experimental
groups, showing MPs loaded with MOG and DXM are superior
at ameliorating disease compared with the other groups. In
particular, DXM/MOG/MPs were superior to DXM/MPs,
suggesting that antigen is required in amelioration of the
disease. This possibly occurs through inhibition of disease-
associated cytokine production. Our data indicates that MOG
stimulated splenocytes from EAE immunized mice treated with
DXM/MOG/MPs had significantly lower production of both
IL-17 and GM-CSF (Figure 5); however, these mice did not
have a significant difference in intracellular splenocytes IFN-γ
production (Figure S5). Additionally, there was no significant
difference in FoxP3+ T-regulatory cells or intracellular IFN-γ
and IL-17 in the spinal cord or inguinal lymph nodes (Figures
S2 and S3). Other previous studies have indicated that FoxP3+
T-regulatory cells have a primary role in autoimmune
treatment, when the tolerogenic adjuvant and antigen are
given prophylactically or at the time of disease induction. Kang
et al. previously showed that administration of unencapsulated
DXM and protein antigen allowed for protection against
delayed-type hypersensitivity and diabetes onset.43 With
prophylactic administration of the compounds, induction of
tolerogenic DCs and FoxP3+ T-regulatory cells occurred.43
Fissolo et al. reported that a MOG-based DNA vaccine
administered prophylactically to EAE immunized mice had a
significant protective effect, decreasing the overall clinical score
through FoxP3+ T-regulatory cell expansion and concomitant
decreases in IL-17 and IFN-γ expression.44 Although we saw no
changes in regulatory T cell populations with treatment,
interestingly, our DXM/MOG/MPs induced regulatory T cell
formation and limited the progression of EAE, when given
prophylactically (data not shown). Previous work with
biomaterials and an immunomodulating peptide has shown
both prophylactic EAE protection23 and protection after
immunization, but prior to EAE symptom onset.27 Admin-
istration of gold-based nanoparticles containing a tolerogenic
small molecule and an epitope of MOG resulted in decreased
IFN-γ, IL-6, and IL-17, as well as increased levels of FoxP3+ T-
regulatory cells.26 As previously stated, we saw no significant
change in FoxP3+ populations with our treatment study, and
the mechanism of treatment has not been previously reported
with a similar study. Therapeutic treatment with the
aforementioned MOG-based DNA vaccine at 10 and 24 days
after disease immunization displayed significant inhibition of
EAE progression and diminished symptoms; however Fissolo et
al. make no mention of mechanisms with regard to therapeutic
action.44 Although both prophylactic and therapeutic treat-
ments have been shown to work, very little has been elucidated
on a therapeutic mechanism. Wegmann et al. showed
dendrimers containing a synthetic peptide therapeutically
protected mice against experimental allergic encephalomyelitis;
however, unlike our study they showed an increase in IL-17
generated by splenocytes.25 In a recent promising study, Getts
et al. have suggested that encephalogenic peptide-based EAE
therapies work through an increase in T cell anergy.24 T cell
anergy is a process where T cells are inactivated in the
periphery, possibly through co-stimulatory inhibition between
APCs and T cells.45 Co-stimulatory inhibition has been
associated with DXM.45 Classically, anergeric cells do not
respond to antigen; however, Figure 5 shows that with antigen
stimulation significant levels of cytokines are produced. This
antigen specific response indicates that perhaps anergy might
not be the mechanism of action, but further work would need
to be performed to fully rule-out anergy as a mechanism of
action for therapeutic-based EAE treatments.
Here we report that one possible contribution to the
protective effects of DXM/MOG/MPs is the significant
decrease in production of IL-17 and GM-CSF from antigen
stimulated splenocytes (Figure 5). IL-17 is an important
cytokine in autoimmune disorders, and Yan et al. have recently
shown CNS-specific inhibition of IL-17 protects against EAE
without diminishing the entire immune system.46 A study by
Komiyama et al. also suggests IL-17 may play a more significant
role in EAE than that of IFN-γ.47 Additionally, GM-CSF has
functioned to increase activation of CNS-associated APCs,48 to
enhance the survival of Th17 cells,49 and may possibly function
in IL-17 and IFN-γ independent roles to exacerbate disease.50
Although this study suggests IL-17 and GM-CSF playing a
possible role in the protective functions of DXM/MOG/MPs
in EAE treatment, there are other possible mechanisms of
tolerance that need to be explored.
A further mechanism could include expression of trans-
forming growth factor β (TGF-β), a cytokine that has
previously been shown to inhibit the trafficking of disease-
causing effector cells.51 Also, it is possible that a less well-
studied regulatory T cell subset could be involved, such as
CD8+FoxP3− cells, which suppress EAE through TGF-β
mediated mechanisms.52 Other ways that T-effector cell
function may be inhibited is by T cell anergy (vide supra) or
T cell deletion. Glucocorticoids, such as DXM, have been
shown to induce thymocyte death.53 Repetitive exposure to
antigen has also been shown to induce T cell deletion.54 Due to
the significantly lowered mean clinical score of the DXM/
MOG/MPs group and the lowered mean clinical score of the
MOG/MPs group, it is possible that repetitive MOG or DXM
exposure may result in some level of T cell deletion. Future
work should be performed to try and elucidate through what
mechanisms therapeutic treatments act to provide protection
from autoimmune disorders such as MS.
■ CONCLUSIONS
Here we report encapsulation of MOG peptide and DXM into
Ac-DEX MPs to therapeutically treat EAE, a model of MS. We
showed encapsulated DXM was more efficient at decreasing in
vitro immune responses to LPS using both Mϕ and primary
BMDCs. Furthermore, mice immunized for EAE were treated
with Ac-DEX MPs coencapsulating DXM and MOG peptide.
This therapy significantly reduced the disease clinical score and
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expression of IL-17 and GM-CSF, two inflammatory and
disease-associated cytokines. Additionally, we show DXM/
MOG/MPs were superior to free DXM and MOG at
ameliorating disease which indicated encapsulation of these
compounds provides for more efficient delivery to the desired
cellular populations, in vivo. Treatment of EAE after symptom
onset by subcutaneous injection of DXM and disease-associated
peptide in a polymeric delivery vehicle provides promising new
possibilities for the treatment of MS.
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